Key terms

About DOCS

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DOCS news

Apr 01 4:09pm ET Doximity short report concerns mostly already known, says Evercore ISI Apr 01 9:50am ET Doximity falls after Jehoshaphat questions sales growth in short report Apr 01 9:45am ET Jehoshaphat Research announces short position in Doximity Mar 25 9:41am ET Unusually active option classes on open March 25th Feb 27 11:36pm ET Doximity: A Steady Performer Amid Market Volatility and Operational Uncertainties Feb 26 6:25am ET Doximity initiated with a Market Perform at Leerink Feb 09 9:47am ET Doximity falls -10.2% Feb 09 9:43am ET Doximity price target raised to $27 from $25 at Wells Fargo Feb 09 8:17am ET Doximity (DOCS) Hold Rating Maintained Amid Growth Potential and Market Uncertainties Feb 09 8:17am ET Doximity Growth Prospects and Buy Rating Endorsed Amid Economic Caution Feb 09 7:10am ET Analysts Conflicted on These Healthcare Names: Doximity (DOCS) and AbbVie (ABBV) Feb 09 6:48am ET Doximity (DOCS) Maintains Hold Rating Amid Mixed Growth Signals and Potential Catalysts Feb 09 6:47am ET Doximity Sell Rating: Concerns Over Q4 Guidance and Market Share Outlook Feb 09 6:43am ET Doximity price target raised to $31 from $29 at Baird Feb 08 4:05pm ET Doximity sees FY24 revenue $473.3M-$474.3M, consensus $467.3M Feb 08 4:04pm ET Doximity sees Q4 revenue $115.9M-$116.9M, consensus $117.9M Feb 08 4:04pm ET Doximity reports Q3 EPS 24c, consensus 23c Feb 08 3:19pm ET Doximity options imply 11.0% move in share price post-earnings Feb 07 7:47am ET Doximity price target lowered to $29 from $32 at BofA Feb 07 6:40am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Edwards Lifesciences (EW) and Doximity (DOCS) Feb 01 6:37am ET Doximity: Navigating Uncertainties in Digital Ad Market Growth and Competitive Challenges Jan 24 7:41am ET Analysts Conflicted on These Healthcare Names: Intuitive Surgical (ISRG), Madrigal Pharmaceuticals (MDGL) and Doximity (DOCS) Jan 23 9:23am ET Doximity price target raised to $32 from $29 at BofA Jan 23 6:07am ET Doximity’s Hold Rating Maintained Amidst Market Optimism and Growth Challenges Jan 07 9:26pm ET Truist Financial Keeps Their Hold Rating on Doximity (DOCS) Jan 07 5:34am ET BTIG Sticks to Their Hold Rating for Doximity (DOCS)

DOCS Financials

1-year income & revenue

Key terms

DOCS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DOCS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms